Morpholine

Morpholine

SCHEMBL1198041

C1COCCN1.CCN(Cc1ccccc1)C(CCP(=O)(O)O)CCP(=O)(O)O

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.35
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
OPRD1 P41143 3/20 0.33
KDM4E B2RXH2 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
BCHE P06276 1/20 0.32
ANPEP P15144 2/20 0.32
ERAP1 Q9NZ08 2/20 0.32
ALDH1A1 P00352 2/20 0.32
ERAP2 Q6P179 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL1198843 0.93 S1PR2 (0.38) S1PR2S1PR4S1PR1S1PR3CYP2C9
SCHEMBL1198741 0.87 S1PR2 (0.43) S1PR2S1PR4S1PR1S1PR3OPRD1
Morpholine SCHEMBL1197346 0.86 GRIN2D (0.39) S1PR2S1PR4S1PR1S1PR3KDM4E
SCHEMBL1197672 0.78 S1PR2 (0.48) S1PR2S1PR4S1PR1S1PR3ANPEP
SCHEMBL1198018 0.70 S1PR2 (0.46) S1PR2S1PR4S1PR1S1PR3KDM4E
Ammonia Solution, Strong SCHEMBL1197667 0.65 ALDH1A1 (0.39) LMNACYP3A4CYP2D6ANPEPERAP1
SCHEMBL12126189 0.65 TSHR (0.48) OPRD1KDM4ESLC6A2SLC6A4LMNA
Morpholine SCHEMBL3142248 0.64 KDM4E (0.48) CYP2C9KDM4EANPEPERAP2MEN1
SCHEMBL8069172 0.64 OPRD1 (0.50) OPRD1LMNABCHEKMT2AOPRK1
SCHEMBL11540558 0.63 ANPEP (0.48) ANPEPERAP1ALDH1A1ERAP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND EKIMOTO HISAO 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND NR3C2, NR3C1, MC5R S1PR2 3219/4885S1PR4 3431/4885S1PR1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.